Keverprazan

Keverprazan
Clinical data
Other namesKeprason
Legal status
Legal status
  • Rx in China
Identifiers
  • 1-[5-(2-fluorophenyl)-1-[3-(3-methoxypropoxy)phenyl]sulfonylpyrrol-3-yl]-N-methylmethanamine
    or 1-(5-(2-fluorophenyl)-1-(3-(3-methoxypropoxy)phenyl)sulfonylpyrrol-3-yl)-N-methylmethanamine
CAS Number
PubChem CID
IUPHAR/BPS
UNII
Chemical and physical data
FormulaC22H25FN2O4S
Molar mass432.51 g·mol−1
3D model (JSmol)
  • CNCC1=CN(C(=C1)C2=CC=CC=C2F)S(=O)(=O)C3=CC=CC(=C3)OCCCOC
  • InChI=1S/C22H25FN2O4S/c1-24-15-17-13-22(20-9-3-4-10-21(20)23)25(16-17)30(26,27)19-8-5-7-18(14-19)29-12-6-11-28-2/h3-5,7-10,13-14,16,24H,6,11-12,15H2,1-2H3
  • Key:UDHVRDAZIAGHFG-UHFFFAOYSA-N

Keverprazan is a drug for the treatment of duodenal ulcers, gastroesophageal reflux disease (GERD), and H. pylori eradication. It is approved for clinical use in China.[1][2]

References

  1. ^ "Fosun Pharma and Carephar Enter into a Global Collaboration to Co-develop and Exclusively Commercialize China's First Self-Developed P-CAB Product Keverprazan Hydrochloride". fosunpharma.com. 19 September 2022.
  2. ^ Kang C (May 2023). "Keverprazan Hydrochloride: First Approval". Drugs. 83 (7): 639–643. doi:10.1007/s40265-023-01865-w. PMID 37074491.
This article is issued from Wikipedia. The text is available under Creative Commons Attribution-Share Alike 4.0 unless otherwise noted. Additional terms may apply for the media files.